Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-02-14 6:51 pm Sale | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | ORBIMED ADVISORS LLC | 0 0% | -10,378,591 (Position Closed) | View |
2024-02-14 2:11 pm Unchanged | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Rock Springs Capital Management LP | 39,919,255 5.69% | 0 (Unchanged) | View |
2024-02-14 2:10 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Rock Springs Capital Management LP | 39,919,255 6.38% | 8,694,770 (+27.85%) | View |
2024-02-14 12:36 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | MANGROVE PARTNERS IM LLC | 43,764,465 6.24% | 43,764,465 (New Position) | View |
2024-02-13 5:26 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 36,854,190 5.3% | 32,000 (+0.09%) | View |
2024-02-06 4:15 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Soleus Private Equity Fund III L.P. | 48,887,095 7% | 500,000 (+1.03%) | View |
2024-02-05 5:09 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | ADAGE CAPITAL PARTNERS GP L.L.C. | 50,250,000 7.17% | 50,250,000 (New Position) | View |
2023-11-20 08:45 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 99,704,885 14.22% | 2,378,330 (+2.44%) | View |
2023-11-15 07:56 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 97,326,555 13.88% | 7,200 (+0.01%) | View |
2023-11-13 07:31 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 97,319,355 13.88% | 1,758,195 (+1.84%) | View |
2023-11-08 07:06 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 95,561,160 13.63% | 2,188,575 (+2.34%) | View |
2023-11-06 07:30 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 93,372,585 13.32% | 1,081,380 (+1.17%) | View |
2023-11-02 07:30 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 92,291,205 13.25% | 92,130 (+0.10%) | View |
2023-10-30 6:02 pm Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 92,199,075 13.15% | 2,168,475 (+2.41%) | View |
2023-08-10 4:42 pm Sale | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | BAKER BROS. ADVISORS LP | 14,604,391 2.2% | -54,754,968 (-78.94%) | View |
2023-07-26 4:31 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Soleus Private Equity Fund III L.P. | 48,387,095 7.5% | 48,387,095 (New Position) | View |
2023-06-16 08:00 am Purchase | 13D | MEREO BIOPHARMA GROUP PLC ADR MREO | Rubric Capital Management LP | 90,030,600 14.41% | 6,250,000 (+7.46%) | View |
2023-02-14 4:40 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | ORBIMED ADVISORS LLC | 10,378,591 5.92% | 4,315,246 (+71.17%) | View |
2023-02-14 4:03 pm Sale | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Point72 Asset Management L.P. | 22 0.1% | -10,609,978 (-100.00%) | View |
2023-02-14 4:00 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | BAKER BROS. ADVISORS LP | 69,359,359 9.99% | 4,441,758 (+6.84%) | View |